S
Serge Gauthier
Researcher at McGill University
Publications - 715
Citations - 61038
Serge Gauthier is an academic researcher from McGill University. The author has contributed to research in topics: Dementia & Disease. The author has an hindex of 93, co-authored 637 publications receiving 52775 citations. Previous affiliations of Serge Gauthier include Hamamatsu University School of Medicine & La Salle University.
Papers
More filters
Journal ArticleDOI
Imaging biomarkers for amyloid: a new generation of probes and what lies ahead.
TL;DR: Use of imaging biomarkers such as positron emission tomography with amyloid ligands, particularly in asymptomatic and pre-dementia stages of AD, has been the subject of debate (Dubois et al., 2013), with arguments both for and against the biomarker driven diagnosis of AD.
Journal ArticleDOI
Impact of long- and short-range fibre depletion on the cognitive deficits of fronto-temporal dementia
Melissa Savard,Tharick A. Pascoal,Stijn Servaes,Thijs Dhollander,Yasser Iturria-Medina,Min Su Kang,Paolo Vitali,Joseph Therriault,Sulantha Mathotaarachchi,Andrea Lessa Benedet,Serge Gauthier,Pedro Rosa-Neto +11 more
TL;DR: In this article , the authors used a common factor analysis to extract a semantic and an executive factor to predict cognition in patients with fronto-temporal dementia (FTD) and found that semantic symptoms were mainly dependent on short-range white-matter (WM) fibre disruption, while damage to long-range WM fibres was preferentially associated with executive dysfunction.
Journal ArticleDOI
Treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled trial with a neurotrophic agent
Book ChapterDOI
Effects on Decline or Deterioration
TL;DR: The methodological issues relevant to proof of efficacy for a clinically meaningful stabilization in early, intermediate as well as late stages of AD are critically examined.
Journal ArticleDOI
Cerebrolysin in mild to moderate alzheimer's disease: a meta-analysis of randomized controlled clinical trials
Serge Gauthier,Jefferson Voltaire Proaño,Jianping Jia,Lutz Froelich,Johannes C. Vester,Edith Doppler +5 more
TL;DR: Cerebrolysin was significantly more effective than placebo at 4 weeks regarding cognitive function (4 weeks: SMD -0.40 points; 95% CI - 0.53-0.61; p = 0.0010) and at 4 and 6 months regarding global benefit (combined efficacy criteria; 4 weeks: MW 0.57, 95%CI 0.20-9.21; p= 0.0212; 6 months: OR 4.13, pÕ 0.37 points;95% CI 1.37-18.0031